Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:AMGN - Amgen Stock Price, Forecast & News

$241.49
+0.99 (+0.41 %)
(As of 01/20/2020 04:35 AM ET)
Add
Compare
Today's Range
$239.27
Now: $241.49▼
$242.14
50-Day Range
$232.77
MA: $238.58▼
$243.81
52-Week Range
$166.30
Now: $241.49▼
$244.99
Volume2.51 million shs
Average Volume1.69 million shs
Market Capitalization$143.49 billion
P/E Ratio18.53
Dividend Yield2.41%
Beta1.11
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
Previous Symbol
CUSIP03116210
CIK318154
Webhttp://www.amgen.com/
Phone805-447-1000

Debt

Debt-to-Equity Ratio2.54
Current Ratio2.89
Quick Ratio2.59

Price-To-Earnings

Trailing P/E Ratio18.53
Forward P/E Ratio16.47
P/E Growth2.08

Sales & Book Value

Annual Sales$23.75 billion
Price / Sales6.04
Cash Flow$18.16 per share
Price / Cash Flow13.30
Book Value$19.62 per share
Price / Book12.31

Profitability

EPS (Most Recent Fiscal Year)$14.40
Net Income$8.39 billion
Net Margins34.48%
Return on Equity80.26%
Return on Assets14.50%

Miscellaneous

Employees21,500
Outstanding Shares594,180,000
Market Cap$143.49 billion
Next Earnings Date1/30/2020 (Confirmed)
OptionableOptionable

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:AMGN Rates by TradingView

(Ad)


In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, December 11th. Investors of record on Friday, February 14th will be paid a dividend of $1.60 per share on Friday, March 6th. This represents a $6.40 annualized dividend and a yield of 2.65%. The ex-dividend date is Thursday, February 13th. This is an increase from Amgen's previous quarterly dividend of $1.45. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen declared that its Board of Directors has initiated a share buyback program on Friday, February 2nd 2018, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's leadership believes its stock is undervalued.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Tuesday, October, 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.53 by $0.13. The medical research company had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. Amgen's quarterly revenue was down 2.8% on a year-over-year basis. During the same period last year, the firm posted $3.69 EPS. View Amgen's Earnings History.

When is Amgen's next earnings date?

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Amgen.

How can I listen to Amgen's earnings call?

Amgen will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of $$14.50-14.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $$14.44. The company issued revenue guidance of $$23.1-23.3 billion, compared to the consensus revenue estimate of $$23.01 billion.

What price target have analysts set for AMGN?

21 analysts have issued 1-year target prices for Amgen's stock. Their forecasts range from $198.00 to $277.00. On average, they anticipate Amgen's share price to reach $236.29 in the next year. This suggests that the stock has a possible downside of 2.2%. View Analyst Price Targets for Amgen.

What is the consensus analysts' recommendation for Amgen?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
  • 2. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)
  • 3. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019)
  • 4. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019)
  • 5. Cantor Fitzgerald analysts commented, ". We Reiterate our Neutral rating and $221 Price Target. We are attending the AACR (cancer research meeting) in Atlanta. Amgen presented its preclinical data for 24-minute session. The company’s molecule is targeting the KRAS p.G12C mutation and is a covalent inhibitor. The presentation explained how it identified a unique groove formed by rotation of an adjacent histidine residue (H95). An inactive form of KRAS reveals a small pocket P2 in GDP-KRAS, which is adjacent to cys12. The molecule binds to P2 and H95 and is expected to be dosed orally once daily. 510 has single-digit nanomolar potency and is 1,000x more selective to other KRAS mutants." (4/1/2019)

Has Amgen been receiving favorable news coverage?

Press coverage about AMGN stock has been trending positive on Monday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amgen earned a news impact score of 3.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Amgen.

Are investors shorting Amgen?

Amgen saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 9,910,000 shares, an increase of 8.2% from the December 15th total of 9,160,000 shares. Based on an average daily trading volume, of 2,130,000 shares, the days-to-cover ratio is presently 4.7 days. Currently, 1.7% of the company's shares are sold short. View Amgen's Current Options Chain.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), AT&T (T), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Gilead Sciences (GILD).

Who are Amgen's key executives?

Amgen's management team includes the folowing people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
  • Mr. David W. Meline, Exec. VP & CFO (Age 62)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

Who are Amgen's major shareholders?

Amgen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Johanson Financial Advisors Inc. (0.20%), PGGM Investments (0.09%), Douglass Winthrop Advisors LLC (0.05%), Nisa Investment Advisors LLC (0.05%), Gateway Investment Advisers LLC (0.05%) and Manning & Napier Group LLC (0.03%). Company insiders that own Amgen stock include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Commerzbank Aktiengesellschaft FI, Gateway Investment Advisers LLC, Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Creative Financial Designs Inc. ADV, State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar. View Insider Buying and Selling for Amgen.

Which major investors are buying Amgen stock?

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Manning & Napier Group LLC, Fluent Financial LLC, Camelot Portfolios LLC, Sanders Morris Harris LLC, Private Trust Co. NA and Alpha Cubed Investments LLC. View Insider Buying and Selling for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $241.49.

How big of a company is Amgen?

Amgen has a market capitalization of $143.49 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.View Additional Information About Amgen.

What is Amgen's official website?

The official website for Amgen is http://www.amgen.com/.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (NASDAQ AMGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,358 (Vote Outperform)
Underperform Votes:  882 (Vote Underperform)
Total Votes:  2,240
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: What is the S&P/ASX 200 Index?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel